- Home
- SAGE
as 04-25-2025 4:00pm EST
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.
Upcoming Earnings Alert:
Get ready for potential market movements as Sage Therapeutics Inc. SAGE prepares to release earnings report on 29 Apr 2025.
| Founded: | 2010 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 415.0M | IPO Year: | 2014 |
| Target Price: | $9.88 | AVG Volume (30 days): | 1.2M |
| Analyst Decision: | Hold | Number of Analysts: | 19 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -6.59 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.62 - $14.97 | Next Earning Date: | 04-29-2025 |
| Revenue: | $41,243,000 | Revenue Growth: | -52.30% |
| Revenue Growth (this year): | 100.64% | Revenue Growth (next year): | 70.19% |
Latest Sage Therapeutics Inc. News
SAGE Breaking Stock News: Dive into SAGE Ticker-Specific Updates for Smart Investing
Zacks
2 days ago
Analysts Estimate Agios Pharmaceuticals (AGIO) to Report a Decline in Earnings: What to Look Out for
Zacks
4 days ago
Sage Therapeutics, Inc. (SAGE) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Business Wire
11 days ago
Sage Therapeutics to Report First Quarter 2025 Financial Results on Tuesday, April 29, 2025
Zacks
a month ago
Sage Therapeutics (SAGE) Up 7.4% Since Last Earnings Report: Can It Continue?
Business Wire
2 months ago
Sage Therapeutics Announces R&D Leadership Transition
Insider Monkey
2 months ago
Sage Therapeutics, Inc. (SAGE): Among the Best Psychedelic Stocks to Buy in 2025
Insider Monkey
2 months ago
Is Sage Therapeutics, Inc. (SAGE) the Best Small-Cap Growth Stock to Buy Now?
TipRanks
2 months ago
Sage Therapeutics price target lowered to $12 from $14 at Scotiabank
Compare SAGE vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SAGE Sage Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.